Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Atavistik Bio, Inc
Seagen Inc.
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
AbbVie
Tizona Therapeutics, Inc
Genentech, Inc.
Normunity AccelCo, Inc.
Eli Lilly and Company
Institute of Cancer Research, United Kingdom
Jonsson Comprehensive Cancer Center
MacroGenics
UNC Lineberger Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SystImmune Inc.
Pheon Therapeutics
Eli Lilly and Company
Orano Med LLC
Tongji Hospital
Eli Lilly and Company
Fusion Pharmaceuticals Inc.
Innate Pharma
Memorial Sloan Kettering Cancer Center
OncoNano Medicine, Inc.
City of Hope Medical Center
Risen (Suzhou) Pharma Tech Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
Radiopharm Theranostics, Ltd
Therorna
HiFiBiO Therapeutics
TScan Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rondo Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Chongqing Precision Biotech Co., Ltd
Kortuc, Inc.
Nurix Therapeutics, Inc.
Pfizer
Arcus Biosciences, Inc.
GONGCHU Biotechnology Co., Ltd
UNC Lineberger Comprehensive Cancer Center
Adcentrx Therapeutics